Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML). Preclinical
studies were promising but the results of clinical trials by far exceeded expectations …

The BCR-ABL1 oncoprotein transforms pluripotent HSCs and initiates chronic myeloid
leukemia (CML). Patients with early phase (also known as chronic phase [CP]) disease …

Imatinib therapy, which targets the oncogene product BCR-ABL, has transformed chronic
myeloid leukemia (CML) from a life-threatening disease into a chronic condition. Most …

Deregulated oxidative metabolism is a hallmark of leukaemia. While tyrosine kinase
inhibitors (TKIs) such as imatinib have increased survival of chronic myeloid leukaemia …

Every year, more than 8000 new cases of chronic myeloid leukemia (CML) are diagnosed in
the United States. 1 BCR-ABL1, a fusion protein kinase derived from a reciprocal …

Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …

Abstract Dasatinib (BMS-354825), a novel dual SRC/BCR-ABL kinase inhibitor, exhibits
greater potency than imatinib mesylate (IM) and inhibits the majority of kinase mutations in …

Tyrosine kinase inhibitors (TKIs) are highly effective in treatment of chronic myeloid
leukemia (CML) but do not eliminate leukemia stem cells (LSCs), which remain a potential …

Leukemia stem cells (LSCs) in individuals with chronic myelogenous leukemia
(CML)(hereafter referred to as CML LSCs) are responsible for initiating and maintaining …

Imatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients
but does not eliminate leukemia stem cells (LSCs), which remain a potential source of …